Introduction
============

Diabetes mellitus (DM) is a group of chronic metabolic diseases that affects around 425 million people worldwide ([@B105]). It is widely accepted that DM leads to a cascade of long-term severe complications, including cardiovascular diseases, renal failure and blindness ([@B7]). Importantly, cardiovascular diseases account for nearly 70% of deaths in diabetic patients ([@B112]).

Diabetes mellitus can affect cardiac structure and function independently of vascular disease, hypertension or coronary artery disease, leading to the development of a heart disorder termed diabetic cardiomyopathy (DbCM). DbCM is characterized by a series of cardiac structural and functional remodeling, including left ventricular hypertrophy, interstitial fibrosis, lipid deposition, cell death, and decreased systolic dysfunction, which eventually lead to heart failure ([@B2]; [@B119]; [@B98]). In addition to contractile function, DbCM can also disrupt cardiac electrical activity, leading to arrhythmia ([@B50]) and sudden cardiac death. It has been reported that patients with diabetes have a significantly increased risk of arrhythmogenesis compared with the general population ([@B47]). Indeed, DbCM has become a major contributor to mortality in diabetic patients ([@B19]; [@B30]). Moreover, abnormal mitochondrial morphology (e.g., fragmented organelle, mottled matrix, and damaged membrane) and energetics have been observed in diabetes patients with arrhythmia ([@B80]; [@B81]), suggesting that mitochondrial dysfunction could contribute to arrhythmogenesis in the setting of DbCM.

In this mini view, we revisit some of the main features of DbCM, focusing on pathophysiological mechanisms associated with cardiac mitochondrial dysfunction, oxidative stress and fibrosis, and their proarrhythmic roles in DbCM.

Mitochondria and Oxidative Stress in Diabetic Cardiomyopathy
============================================================

Mitochondria are the major powerhouse in cardiomyocytes, producing more than 95% of energy in the form of adenosine triphosphate (ATP). ATP is formed from adenosine diphosphate (ADP) and inorganic phosphate (Pi) by F~0~F~1~ ATP synthase (complex V), which uses the electrochemical gradient generated by the electron transport chain (complexes I to IV) driven by NADH produced in the tricarboxylic acid (TCA) cycle (Figure [1](#F1){ref-type="fig"}). ATP is transported into cytosol via adenine nucleotide translocator (ANT) and hydrolyzed to support cellular mechanical work (excitation and contraction), ion homeostasis, and molecular synthesis ([@B88]). Importantly, mitochondria are also a major source of reactive oxygen species (ROS) production ([@B18]), likely at complex I and complex III ([@B85]; Figure [1](#F1){ref-type="fig"}). While physiological level ROS is essential for cellular redox signaling ([@B106]), excessive ROS are toxic and can affect large molecules such as redox sensitive ion channels \[e.g., ryanodine receptors (RyRs), sarcoplasmic reticulum (SR) Ca^2+^ transport ATPase (SERCA) and L-type Ca^2+^ channels (LCCs)\]. Furthermore, mitochondria can directly regulate cytosolic Ca^2+^ via mitochondrial Ca^2+^ uniporter (mCU) and Na^+^/Ca^2+^ exchanger (mNCE). Not surprisingly, loss of mitochondrial function has been implicated to be closely associated with a variety of human diseases including DM ([@B8]; [@B50]). In particular, studies have revealed that mitochondrial functional and structural alterations, including redox signaling, energy production, biogenesis, dynamics, and quality control, are important contributing factors to the pathogenesis of DbCM ([@B92]).

![The scheme of mitochondrion and its interaction with other subcellular systems in cardiomyocyte. The major function of mitochondrion is to produce ATP, which occurs at complex V (*a.k.a.* F0F1 ATPase) using the electrochemical gradient generated by electron transport chain (complex I to IV). A byproduct of ATP production is superoxide (O~2~^.-^), which is probably generated at complex I and complex III. ATP is translocated to cytosol via ANT and hydrolyzed to support excitation-contraction and energy-sensitive ion transporters (indicated by green dashed lines). O~2~^.-^ can freely diffuse to cytosol and form ROS, which can modify a variety of redox sensitive ion transporters (indicated by red dashed lines). Altogether, mitochondrial dysfunction-associated ATP depletion and ROS accumulation can significantly affect cellular action potentials and ion homeostasis. ROS, reactive oxygen species; CaMKII, Ca^2+^/calmodulin-dependent protein kinase II; SR, sarcoplasmic reticulum; TCA, tricarboxylic acid; ANT, adenine nucleotide translocator; mCU, mitochondrial Ca^2+^ uniporter; mNCE, mitochondrial Na^+^/Ca^2+^ exchanger; I--V, complex I to complex V.](fphys-09-01670-g001){#F1}

Oxidative stress is a hall marker of mitochondrial dysfunction, which is known to damage a variety of intracellular macromolecules, leading to lipid peroxidation and detrimental protein modifications ([@B131]). Increased ROS levels may also activate multiple redox-sensitive signaling pathways involved in DbCM-relevant cardiac dysfunction, leading to impaired intracellular Ca^2+^ regulation, fibrosis, and loss of essential trace metal homeostasis. In the cardiomyocytes, the major site of ROS production is mitochondria ([@B18]; [@B85]). In patients with diabetes, as glucose utilization is greatly impaired, the heart relies almost exclusively on fatty acids oxidation (FAO) to produce ATP. The switching to FAO leads to increased ROS production in DM ([@B15]). Another important source of ROS production in DbCM is the hyperglycemia-induced advanced glycation end-products (AGEs) ([@B91]). In addition, it has been shown that inhibiting protein kinase C (PKC)-α signaling pathway reduces ROS levels and alleviates oxidative stress damage in DbCM in rats, suggesting that PKC-α is involved in ROS production in DM ([@B79]).

Mitochondrial-Associated Cardiac Arrhythmia
===========================================

Cardiac arrhythmia refers to conditions in which the heart's normal rhythm is disrupted, or the electrical activity is abnormal. Cardiac arrhythmias are traditionally considered to occur due to an abnormality in impulse initiation and/or electrical propagation. Abnormal impulse initiation is associated with triggered activity (i.e., trigger) resulting from premature activation of cardiac tissues by afterdepolarizations (e.g., early afterdepolarizations, EADs or delayed afterdepolarizations, DADs) or enhanced automaticity in the pacemaker cells, which may propagate as focal activity. Abnormal impulse propagation is associated with block of conduction or re-entry, which occurs when a single propagating impulse traveling through the heart gives rise to two or more propagated responses through wave-breaks. Reentrant arrhythmias can be attributed to three main cellular mechanisms: (i) loss of cell to cell electrical coupling and communication by closure of gap junctions, (ii) regional uncoupling caused by anatomical barriers such as scar tissue, and (iii) dynamic functional block due to heterogeneity of intrinsic electrophysiological restitution properties. The detailed review of mechanism of cardiac arrhythmogenesis can be found here ([@B4]; [@B104]).

While arrhythmia is a leading cause of sudden cardiac death in patients with diabetes ([@B24]; [@B23]), the precise molecular mechanisms underlying cardiac arrhythmogenesis in DbCM are poorly understood, hindering the development of effective therapeutic strategy. Recently, the loss of mitochondrial function, which is often observed in DbCM, has emerged as a key contributor to the arrhythmogenic substrates ([@B64]; [@B118]), probably via modulating the redox and/or energy sensitive signaling pathways that regulate ion handling channels/transporters ([@B73]; [@B123]; [@B135], [@B134]).

Oxidative Stress-Associated Arrhythmic Substrates
-------------------------------------------------

Although hyperglycaemia regulates multiple pathways associated with the pathogenesis of DbCM, oxidative stress is considered as a central mechanism underlying the adverse remodeling in diabetic hearts ([@B68]), including electrophysiological alternations ([@B64]; [@B55]). Both *in vitro* and computational studies have shown that ROS cause action potential duration (APD) prolongation and induce EADs or DADs in guinea pig ([@B69]; [@B65]) and rabbit cardiomyocytes ([@B119]), leading to focal activity. ROS can also promote reentry via heterogeneous APD prolongation ([@B82]). It is worth noting that both reentry and focal activity account for ROS-mediated arrhythmogenesis.

At the cellular level, the proarrhythmic effect of ROS is attributed to their capability to modulate multiple redox ion channels/transporters underlying ion handling and action potentials ([@B43]; [@B139]; [@B110]), which include RyRs ([@B34]; [@B39]; [@B123]; [@B134]), SERCA ([@B83]; [@B139]), voltage-gated Na^+^ channels (Na~v~) ([@B67]; [@B51]), K^+^ channels (K~ir~ and K~v~) ([@B132]), Na^+^/Ca^2+^ exchanger (NCX) ([@B11]), and LCCs ([@B9]; [@B22]; [@B86]; [@B113]; [@B61]; [@B139]). One of the most well-characterized redox-sensitive ion transporters is RyRs, which have 89 cysteine residues, of which approximately 21 are susceptible to oxidation by free radicals ([@B120]). Studies have shown that extracellular H~2~O~2~ activates RyRs, leading to increased SR Ca^2+^ release in rat ([@B39]; [@B89]) and sheep ([@B34]) ventricular myocytes. Moreover, recent studies have shown that mitochondrial-derived ROS (mdROS) are closely correlated with enhanced Ca^2+^ sparks in resting guinea pig cardiomyocytes ([@B123]; [@B134]). In addition to RyRs, ROS can affect SR Ca^2+^ uptake. It has been shown that ROS inhibit SERCA activity by directly oxidizing its thiol groups ([@B83]; [@B139]). Thus, ROS, by simultaneously activating RyRs and inhibiting SERCA, may lead to increased Ca^2+^ transients ([@B114]; [@B65]). With regards to diabetes, studies have found that free fatty acids-induced mdROS contributes to Ca^2+^ dysregulation, likely by triggering aberrant endoplasmic reticulum/SR Ca^2+^ release, leading to increased DADs and probability of focal excitation ([@B93]; [@B72]).

Sarcoplasmic Na^+^ channels encoded by the SCN5A gene are key to cardiac excitability and rapid impulse propagation. [@B100] have demonstrated that the late Na^+^ current is involved in H~2~O~2~-induced APD prolongation, EADs and DADs in both guinea pig and rabbit cardiomyocytes. Another study showed that ranolazine, a late Na^+^ current blocker, suppressed ROS-mediated EAD and arrhythmias ([@B82]). Importantly, while ROS-induced increase in late Na^+^ current can elicit EADs and arrhythmia, increased ROS may downregulate the total Na^+^ channel expression, resulting in reduced Na^+^ currents and conduction velocity, providing substrates for reentry ([@B67]).

In addition to directly modulating redox sensitive ion channels/transporters, ROS can also indirectly influence ion homeostasis and consequently action potentials via redox signaling such as Ca^2+^/calmodulin dependent kinase II (CaMKII) oxidation. CaMKII is a ubiquitously expressed multifunctional protein kinase that can be activated by binding to Ca^2+^/calmodulin ([@B129]; [@B110]). Recent studies suggest that CaMKII can also be activated by ROS ([@B36], [@B35]; [@B46]; [@B53]), leading to phosphorylation of a wide range of ion handling proteins such as Na^+^ channels ([@B109], [@B111]), LCCs ([@B33]; [@B45]; [@B40]; [@B14]), RyRs ([@B75]; [@B116]; [@B41]; [@B59]; [@B74]; [@B94]; [@B42]), and phospholamban ([@B10]; [@B74]; [@B94]). [@B119] have showed that H~2~O~2~ perfusion-induced oxidative CaMKII activation leads to afterdepolarizations in isolated rabbit cardiomyocytes, likely via phosphorylation of Na^+^ channels and LCCs. In a computational study, [@B124] reported that mdROS-mediated oxidative CaMKII activation induces EADs in guinea pig cardiomyocytes by enhancing the late component of Na^+^ current. The proarrhythmic role of CaMKII oxidation in diabetic hearts has been demonstrated in a recent study showing that selective genetic blocking of CaMKII oxidation prevents the enhanced atrial fibrillation (AF) risk ([@B78]), which has been implicated to be associated with increased mortality in response to myocardial infraction ([@B71]). Redox signaling can also regulate several pro-arrhythmic transcription factors such as nuclear factor-κB (NF-κB), one of the key transcriptional regulators that mediates gene expressions under stress conditions including diabetes. Importantly, Dudley and colleagues have shown that the promoter region of the SCN5A gene encoding cardiac Na^+^ channels contains a NF-κB binding domain, suggesting that SCN5A can be regulated by NF-κB in response to oxidative stress ([@B96]).

Energy Deficiency-Associated Arrhythmias
----------------------------------------

Studies have shown that oxygen consumption rate and ATP synthesis are reduced in patients with insulin resistance ([@B103]) and animals fed with high palmitate ([@B121]), which can contribute to the development of arrhythmia. A series of studies by O'Rourke's laboratory have convincingly demonstrated that mitochondrial depolarization-induced ATP depletion elicits reentrant arrhythmias via a mechanism termed "metabolic sink" ([@B2]; [@B16]; [@B5]; [@B137]). In particular, they showed that decreased ATP levels, or increased ADP/ATP ratio, caused by mitochondrial depolarization, leads to rapid activation of the sarcoplasmic potassium-sensitive K~ATP~ (K~ATP~) channels, causing shortening of APD and reduction of action potential amplitude (APA) ([@B135]). When a threshold of opening K~ATP~ channels is reached, cardiomyocytes are rendered completely inexcitable. They further showed that mitochondrial oscillations \[a phenomena involving local oxidative stress-induced cyclic changes in mitochondrial membrane potential, NADH oxidation and ROS production ([@B6]; [@B136]; [@B137])\] cause highly correlated, repetitive activations of the K~ATP~ channels and fluctuations in both APD and APA ([@B135]), indicating that there is a direct link between mitochondrial energetic dysfunction and arrhythmia. At the tissue level, regional mitochondrial depolarization and K~ATP~ current activation can create inhomogeneous regions or "metabolic sink," in which the increased dispersion of repolarization enhances the vulnerability to reentry, as revealed by both experimental studies ([@B2]) and computer simulations ([@B137]).

Other ATP-sensitive ion transporter proteins include SERCA and sarcoplasmic Na^+^/K^+^ ATPase. It has been shown that expression of ATP2A2 gene that encodes SERCA2a, an isoform mainly expressed in cardiomyocytes, is reduced in DbCM ([@B101]). Studies also showed that reduced mitochondrial ATP production suppresses SERCA activity ([@B62]; [@B29]). The decreased SERCA2a activity and expression present in the diabetic myocardium has been considered as a main contributing factor to impaired Ca^2+^ cycling and aberrant action potentials. Similarly, ATP depletion can decrease Na^+^/K^+^ ATPase activity ([@B138]), an electrogenic pump on sarcoplasmic membrane, leading to not only dysregulation of ion homeostasis but also alteration of the membrane potential.

In addition to influence cellular ion channels and action potentials, decreased ATP production can alter intercellular coupling via gap junctions. Gap junctions are hemichannels in the heart that form electrical connection between cells, mediating the spread of electrical impulse and coordinated contraction of cardiac chambers (see review [@B99]). Connexin 43 (Cx43) is the major component of gap junctions in the ventricular myocytes. In heart failure, the level of Cx43 expression is reduced, which is associated with depressed AP propagation and increased incidence of lethal ventricular arrhythmias. At the single channel level, studies have shown that Cx43 conductance can be inhibited by decreased intracellular ATP concentration in guinea pig ([@B102]) and rat ([@B32]) cardiomyocytes, among others (see review [@B95]), causing suppression of intercellular electrical conductance. It is worth mentioning that gap junction conductance can also be impaired by oxidative stress ([@B12]; [@B51]).

Mitochondrial Dysfunction, Fibrosis and Atrial Fibrillation in Diabetes
=======================================================================

Cardiac fibrosis is characterized by fibroblasts accumulation and excessive deposition of extracellular matrix (ECM) that greatly increases the stiffness of the heart wall and reduces the contractility and compliance of cardiac muscle ([@B37]). Myocardial fibrosis is increasingly recognized as one of the major factors contributing to the pathogenesis of DbCM ([@B97]). In addition, fibrosis, particularly atrial interstitial fibrosis, increases vulnerability to arrhythmia because of delayed discontinuous and zig-zag conduction and unidirectional conduction block ([@B28]; [@B87]).

Mitochondrial Dysfunction and Pathogenesis of Cardiac Fibrosis in DbCM
----------------------------------------------------------------------

In the heart, fibrosis can be activated by multiple sources, including increased mechanical stretch ([@B38]), dysregulated redox signaling ([@B26]), paracrine cytokines from injured cells ([@B128]), and infiltration of circulatory immune cells ([@B49]). Among those, the transforming growth factor β1 (TGF-β1) is recognized as a major fibrogenic factor. In diabetes, hyperglycemia changes the levels of microRNAs and long non-coding RNAs expression, which can contribute to TGF-β activation ([@B128]). TGF-β activity can also be increased by high glucose-induced activation of transcriptional co-regulator p300 ([@B17]), sustained hyperglycemia ([@B117]; [@B122]), and activation of matrix metalloproteinases (MMP), a family of ECM proteolytic enzymes ([@B27]; [@B63]). Activated TGF-β1 binds to its membrane receptors phosphorylates transcription factors SMAD2/3, which activates the canonical (SMAD-dependent) fibrogenic pathway ([@B107]; [@B56]), leading to myofibroblast differentiation and fibrosis ([@B66]). TGF-β1 can also stimulate endothelial-to-mesenchymal transition (EndMT) through convergence of SMAD-dependent and SMAD-independent signaling ([@B77]). Activated EndMT can increase the expression levels of mesenchymal markers, such as α-smooth muscle actin (α-SMA), fibroblast-specific protein-1, and vimentin ([@B76]), promoting cardiac fibrosis in diabetic hearts. Importantly, studies have implicated an interplay between TGF-β1 signaling and mitochondrial dysfunction and associated redox signaling ([@B25]). On one hand, TGF-β1 can upregulate NADPH oxidase 4 (NOX4) expression, resulting in increased mitochondrial ROS production ([@B52]). On the other hand, mdROS have been shown to activate TGF-β1 signaling ([@B60]). Thus, there is a positive feedback mechanism between TGF-β1 and mitochondrial-associated ROS production, facilitating the amplification of the profibrogenic TGF- β1 signaling in DbCM ([@B31]; [@B3]).

In addition to TGF-β1, some members of the mitogen-activated protein kinase (MAPK) family and protein kinase B (Akt)/glycogen synthase kinase-3β (GSK-3β) signaling, are also involved in myocardial fibrosis ([@B126]; [@B127]). Suppression of the MAPKs signaling or the Akt/GSK-β signaling has been shown to ameliorate myocardial fibrosis in diabetes ([@B70]; [@B133]). The PKC, which is activated under oxidative stress, can also contribute to myocardial fibrosis by activating NF-κB and the sequential collagen accumulation ([@B13]). The inhibition of redox sensitive NF-κB signaling has been shown to attenuate hyperglycemia-induced cardiac injuries ([@B20]).

In summary, mdROS, which is increased in diabetic human atrial tissue ([@B3]), could play important roles in the pathophysiology of cardiac fibrosis in DbCM, among many other contributing factors, likely through regulating various redox signaling pathways.

Cardiac Fibrosis and Atrial Fibrillation in DbCM
------------------------------------------------

Atrial fibrillation (AF) is characterized by rapid and uncoordinated atrial activity that causes ineffective atrial contraction. As the most common sustained arrhythmia in clinical practice, AF causes major cardiovascular morbidity and mortality in DM patients ([@B55]). A recent cross sectional survey in China reported that the prevalence of AF in patients with DM is significantly higher than those without known DM ([@B44]). Another study in Japan showed the similar findings that the incidence of AF in diabetic patients is much higher than in the control group ([@B48]).

Recently, DbCM-related excessive fibrosis has emerged as a hallmark and independent risk factor for both triggering and sustaining AF ([@B84]). Myocardial fibrosis in the atrial tissue can elicit AF by causing abnormal cell coupling, which has been observed in DM patients. Cardiac fibroblasts (CF) are non-excitable cells that obstruct the orderly spread of electrical impulse in the hearts by producing an insulating layer of ECM to physically separate groups of myocytes. Thus, excessive CF forms collagen-rich myocardial tissue that causes reduced inter-cardiomyocyte coupling and increased axial resistance, leading to impaired propagation of cardiac action potentials and formation of reentrant excitations. On the other hand, CF can couple to myocytes via gap junction proteins Cx43 and connexin-45 ([@B58]; [@B21]) and studies have shown that the level of Cx43 expression increases significantly in diabetic rat myocardium ([@B115]). As CF have a high cell membrane resistance that makes them excellent long-distance conductors ([@B58]), increased coupling between CF and cardiomyocytes will decrease the conduction velocity and induce synchronous spontaneous activity in distant cardiomyocytes ([@B108]; [@B1]). In addition, studies have revealed that atrial effective refractory period (AERP) is shortened in the diabetic rat atrium, which results in increased dispersion of AERP and formation of unidirectional conduction block ([@B90]), predisposing to reentrant AF.

Mitochondrial-Derived Oxidative Stress and Atrial Electrical Remodeling in DbCM
-------------------------------------------------------------------------------

In addition to promoting arrhythmogenesis through enhancing fibrosis and structural remodeling, mdROS are also involved in the proarrhythmic electrical remodeling in DM \[readers are referred to [@B57] and [@B55] for comprehensive reviews\]. For instance, a recent study has shown that dipeptidyl peptidase-4 inhibitor prevents mitochondrial dysfunction (e.g., mdROS production and mitochondrial depolarization) and ameliorates atrial remodeling and arrhythmic substrates in the diabetic rabbits ([@B130]). The potential link between mdROS and atrial remodeling in the setting of DM has also been suggested by another study showing that allopurinol, a xanthine oxidase inhibitor, prevents alloxan-induced atrial interstitial fibrosis, abnormal Ca^2+^ handling and atrial fibrillation inducibility in rabbits ([@B125]). Furthermore, studies have revealed significant alterations of electrical structure such as effective refractory period ([@B90]) and gap junction conduction ([@B54]) in the atrial of diabetic animals. These studies suggest that mitochondrial dysfunction-induced atrial remodeling may underly the onset and maintaining to AF.

Summary
=======

Mitochondrial dysfunction plays a potential role in the generation and maintenance of cardiac arrhythmias in diabetic hearts. The loss of function of mitochondria is associated with not only reduced ATP production, increased ROS production and acute changes in ion levels, but also dysregulation of multiple signaling pathways regulating transcript expression and fibrosis. All of those could contribute to cardiac arrhythmogenesis (Figure [2](#F2){ref-type="fig"}), suggesting that mitochondria could be an upstream therapeutic target for treatment of arrhythmias in DbCM.

![Summary of the potential mechanisms underlying the proarrhythmic role of mitochondrial dysfunction in diabetes mellitus.](fphys-09-01670-g002){#F2}
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